Epigral Ltd
Epigral Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
From Epigral Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a volume growth of around 10% to 12% for FY27.
- Revenue growth is expected to improve over FY26, with FY27 anticipated to be better than FY26 in terms of volume and value growth.
- Capacity additions, especially commissioning of CPVC and Epichlorohydrin (ECH) units, are on track and expected to support growth.
- Gradual ramp-up to optimum utilization levels by FY28 is planned (CPVC approximately 75%, ECH around 80%).
- Chlorotoluene product line is expected to contribute sizably in FY27, with volume ramp-up continuing.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
- They are working on a new greenfield project; site evaluation and due diligence are ongoing with plans to announce the project within the current year to sustain post-FY29 growth.
- No immediate plans to expand caustic soda capacity, but future capacity increase possible if required.
- The company follows a cautious, step-by-step capex approach, announcing new projects as existing ones near completion.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…
- Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…
- Innovassynth Technologies (India) Ltd (Q4 FY26)
Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…
Frequently Asked Questions
What were Epigral Ltd Q4 FY26 results?
The company targets a volume growth of around 10% to 12% for FY27. Epigral targets a volume growth of around 10% to 12% for FY27, driven by capacity expansions in higher value products like CPVC and ECH.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral is commissioning capacity expansion projects for Epichlorohydrin (ECH) and CPVC in Q2 FY27, expected to ramp up gradually and reach optimum utilization (CPVC ~75%, ECH ~80%) by FY28.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.